Cedars-Sinai spearheads first national certification program for COE staff at cancer centers
The NCI Cancer Center Support Grant requires community outreach and engagement, but the design and implementation of COE programs, as well as staff training, are largely left to individual institutions.
Larry Einhorn, pioneer of platinum-based chemotherapy, discusses 50 years of cancer treatment innovation
When Larry Einhorn was a young physician in the early 1970s, actinomycin-D was the standard drug used to treat testicular cancer.
Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt
Susan Ellenberg started out as a high school math teacher—then became a leading biostatistician
A mathematical puzzle fascinated Susan Ellenberg as a child.
Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo
Latino oncology leaders discuss representation in clinical trials, translational research, and health care
Mesa, Carvajal-Carmona, Cruz-Correa, Perez, Ramirez, Sanchez: “We’re here to help lead and collaborate.”
Tom Lynch reflects on discovery of EGFR mutations’ role in lung cancer
On Nov. 24, 2003, an article in The Boston Globe told the story of a patient’s remarkable response to gefitinib, a drug that had recently been approved by FDA.
AACR progress report highlights AI’s role in research and clinical care
Obstacles to progress include systemic disparities and dwindling appropriations
Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine
Mace Rothenberg has stayed busy since stepping down as Pfizer’s chief medical officer in 2021 by pivoting to an ambitious endeavor in science communication: the Museum of Medicine and Biomedical Discovery.
Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies
Lung cancer couldn’t slow down physician and athlete Lawrence Phillips
Something odd turned up in one of Lawrence Phillips’s routine health screenings in 2008.
Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
What will happen to biomedical research and health care in the aftermath of the 2024 election? The differences in outcomes couldn’t be more stark.
Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa
The White House Cancer Moonshot is committing an additional $100 million to programs focused on reducing cancer burden in African countries.
“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor
Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.
High school science competitions shaped the careers of Regeneron’s co-founders—now, they’re paying it forward
NCI’s Youth Enjoy Science (YES) program also invests in student scientists
At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials
Leaders of three health agencies presented new initiatives focused on patient-centered research, diversity in clinical trial enrollment, and innovation in clinical research.
Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC
Treatment with an indefinite course of osimertinib dramatically improves progression-free survival for patients with stage 3 non-small cell cancer, according to the results of the LAURA trial.
As House prepares cuts for NIH, Rathmell urges Senate to protect funding in FY25
NCI Director Kimryn Rathmell joined the NIH director and four other institute directors in a May 23 Senate subcommittee hearing to craft the Labor-HHS spending bill for fiscal year 2025.